Search results
Showing 1171 to 1185 of 7680 results
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.
Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)
Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.
Palforzia for treating peanut allergy in children and young people (TA769)
Evidence-based recommendations on Palforzia for treating peanut allergy in children and young people.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies.
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)
Evidence-based recommendations on pegcetacoplan (Aspaveli) for treating paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor.
After discussion with Paion AG, NICE is unable to make a recommendation on angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock. The company did not make an evidence submission because of uncertainty about the number of people who would be eligible for treatment. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA859
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)
Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.
Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) (TA576)
NICE is unable to make a recommendation about the use in the NHS of bosutinib (Bosulif) for untreated chronic myeloid leukaemia in adults because no evidence submission was received from Pfizer.
Show all sections
Sections for TA576
NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy because no evidence submission was received from Merck Sharp & Dohme. We will review this decision if the company decides to make a submission
Show all sections
Sections for TA570
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)
Evidence-based recommendations on brigatinib (Alunbrig) for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults who have already had crizotinib.